A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: marks (231), results (1000)

Rituximab SC (12 weekly) Ver1

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

Rituximab (8 weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

Rituximab (12 weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (12 weekly) Regimen Lymphoma – Rituximab (12 Weekly) Indication Non- Hodgkin’s Lymphoma as maintenance monotherapy for relapsed
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-12-weekly.pdf

DasatinibChronic

Description
Chemotherapy Protocol Chronic Myeloid Leukaemia DASATINIB (chronic phase) Funding may be required for specific indications Regimen • CML – Dasatinib (chronic phase) Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/DasatinibChronic.pdf

Bosutinib

Description
Chemotherapy Protocol Chronic Myeloid Leukaemia Bosutinib Regimen • Bosutinib Indication • As an option for the treatment of patients with chronic phase, accelerated
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Bosutinib.pdf

DA_3+8_CADD

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA Ambulatory Regimen AmB - DA (3+8) CADD–Cytarabine-Daunorubicin Regimen • Acute Myeloid Leukaemia – AmB - DA (3
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-3-8-CADD.pdf

Cisplatin Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (Oral) Regimen Ovary-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CisplatinEtoposidePO.pdf

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Uterine-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CisplatinEtoposidePO.pdf

Cisplatin and Topotecan

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-TOPOTECAN (intravenous) Regimen Cervix-Cisplatin-Topotecan IV Indication Recurrent stage IVB cervical cancer in patients who
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CisplatinandTopotecan.pdf

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Cervix-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CisplatinandEtoposidePO.pdf
411 to 420 of 548
Previous … 40 41 42 43 44 … Next